Can one injection challenge daily hot-flash drugs? AbCellera’s ABCL635 faces its first real efficacy test
AbCellera will report Phase 2 ABCL635 data on Aug. 10, testing whether a long-acting NK3 antibody can reduce menopause hot flashes.
Pharma & Biotech
Pharma & Biotech
Can Bonerge’s EquoYouth S-equol study strengthen evidence for menopause relief?
Bonerge Lifescience begins an EquoYouth S-equol menopause study as researchers test whether new data can strengthen a contested supplement case.
Pharma & Biotech
Is Noema Pharma AG building a multi-symptom menopause therapy platform with cendifensine?
Is Noema Pharma AG building a menopause therapy platform? Discover how cendifensine could reshape non-hormonal treatment strategies
Pharma & Biotech
Can Vistagen turn refisolone into a fast-acting alternative for menopausal hot flashes?
Vistagen advances refisolone for menopausal hot flashes after FDA clearance. Find out what this means for non-hormonal treatment options.
Pharma & Biotech
What AbCellera’s upcoming ABCL635 Phase 1 data could reveal about the future of menopause treatment
AbCellera will reveal Phase 1 ABCL635 data on May 11. Read why this menopause drug update could matter for investors and women’s health watchers.
Medical Devices & Diagnostics
Can Peri turn perimenopause tracking into a credible new women’s health device category?
Peri has launched a perimenopause wearable, but can symptom tracking become clinical-grade insight? Read the deeper industry analysis now.
Pharma & Biotech
Can ABCL635 redefine non-hormonal menopause treatment? Inside AbCellera’s Phase 2 push
AbCellera advances ABCL635 into Phase 2 for hot flashes. Find out what this means for non-hormonal menopause care and the biotech’s GPCR strategy.